AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04878211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA COVID-19 vaccine
Description: Pfizer or Moderna mRNA Vaccine
Study NCT04878211 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA COVID-19 vaccine
Description: Pfizer or Moderna mRNA Vaccine
Study NCT04878211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon or glatiramer acetate
Description: iDMT
Study NCT04878211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon or glatiramer acetate
Description: iDMT
Study NCT06164197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thera Trainer Balo
Description: Virtual Reality Based Balance Training Device
Study NCT06164197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Person-Specific Rehabilitation Program
Description: Person-Specific Rehabilitation Program
Study NCT04778371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almonds
Description: 64 g total dry roasted, unsalted almonds per day for a total of 12 weeks
Study NCT04778371 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 g total calorie matched granola bar per day for total of 12 weeks
Study NCT06049134 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV20
Description: Given by Injection into the muscle
Study NCT05797311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation (PNF)
Description: Proprioceptive Neuromuscular Facilitation (PNF) techniques are a therapeutic exercise approach developed based on functional activities in daily life. At the stage of regaining movement and function, it creates models similar to functional activities.
Study NCT05797311 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Shoulder Stabilization Exercises
Description: Scapular stabilization exercise and stabilization exercise for the shoulder joints
Study NCT05270824 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: radical surgery after neoadjuvant immunotherapy
Description: A total or distal gastrectomy with D2 lymph node dissection was done depending on the tumor location after neoadjuvant immunotherapy.
Study NCT05270824 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: radical surgery after neoadjuvant chemotherapy
Description: A total or distal gastrectomy with D2 lymph node dissection was done depending on the tumor location after neoadjuvant immunotherapy.
Study NCT05675774 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dual Energy CT
Description: Patients with acute stroke who receive intervention will undergo dual-energy CT in lieu of single-energy CT at 24 hours post-intervention.
Study NCT06331650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cadonilimab
Description: Cardunnilizumab: the recommended dose is 10mg/kg every 3 weeks on the first day of each cycle; Discontinuation of the drug may be considered if intolerable adverse reactions occur.
Study NCT05452213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: All patients will receive ribociclib in combination with standard endocrine therapy according to the current SmPC and local in-house standard.~Ribociclib will be administered once daily for 21 consecutive days followed by 7 days off treatment (28-day cycle). The daily dose is 600 mg/day.~Ribociclib and standard of care endocrine treatment will be prescribed and administered according to investigator's discretion.
Study NCT04561414 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LED light source system for endoscope
Description: The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use LED light source system for endoscope.
Study NCT04561414 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ureteral stent (Cook Ireland Ltd.)
Description: The prospective, multi-center, single-blind, parallel, randomized controlled superiority trial design is adopted to evaluate the safety and effectiveness of the LED light source system for endoscope during ureter transillumination. The trial will be carried out in 5 centers, with the competitive grouping mode adopted. This trial will be carried out in the General Surgery Department and the Gynecology Department. Totally 120 subjects with rectal cancer, endometriosis, cervical cancer, adenomyosis and pelvic adhesion requiring operation (60 subjects for each of the test group and control group) are involved. The test group use Ureteral stent (Cook Ireland Ltd.).
Study NCT06556030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A
Description: Botulinum Toxin
Study NCT06467032 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: superficial CO2 laser resurfacing
Description: Application of the tested product and comparators on the laser treated side of the back
Study NCT06467032 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laser untreated side
Description: Application of the tested product and comparators on the laser untreated (control) side of the back
Study NCT06556030 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CONTROL
Description: Saline Solution
Study NCT05248360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogen-oxygen mixed gas(H2-O2) inhalation
Description: H2-O2 inhalation, 900ml/min, 2h/d \* 4 weeks (≥5 days/week)
Study NCT05248360 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Air inhalation
Description: Air inhalation, 900ml/min, 2h/d \* 4 weeks (≥5 days/week)
Study NCT05113589 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBM TREATMENT
Description: Participants randomized to this treatment will receive a whole body PBM treatment using a NovoTHOR® whole body light bed. For each treatment session, participants will lie supine in the treatment bed for 20 minutes, with no or minimal attire (underwear). Treatment sessions will be three times weekly for a period of 4 weeks, totalling 12 treatment sessions
Study NCT05113589 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO PBM
Description: The placebo feature of the whole body PBM bed provides controls that select active or placebo (sham) treatments in a way undetectable by participant, operator or observers, such that no-one is aware whether the participant is receiving an active or placebo treatment. There is a switch box that randomises participants to active or placebo; no other randomisation is necessary.
Study NCT05362526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFOT using AIRVO2
Description: The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases. The subjects in this group will receive HFOT at a flow rate of 60-30L liters per minute, maximum concentration of 40%, which will be titrated by bedside nurse to maintain an oxygen saturation of 92% or greater (unless there is a history of COPD and then the clinician can recommend >88%)
Study NCT05362526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: COT
Description: Subjects will be placed on aerosolized trach mask with cool humidification, and titrated to keep oxygen saturation >92% (unless there is a history of COPD and then the clinician can recommend >88%)
Study NCT05860816 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Survey aimed at finding out the barriers and facilitators that Spanish primary care physiotherapists have to implement pain neuroscience-based education programmes in patients with chronic pain.
Study NCT06522932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-GRIP B
Description: Given IV
Study NCT06522932 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Undergo imaging procedure
Study NCT06522932 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optional tumor biopsy
Description: Undergo optional tumor biopsy
Study NCT05915871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan
Description: Tablet for oral administration
Study NCT05915871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth
Description: Capsule for oral administration
Study NCT05915871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicilli
Description: Capsule for oral administration
Study NCT05915871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Tablet for oral administration
Study NCT04823052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulindac (HLX-0201), dose strength 1
Description: Sulindac (HLX-0201) Capsule
Study NCT04823052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulindac (HLX-0201), dose strength 2
Description: Sulindac (HLX-0201) Capsule
Study NCT04823052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule
Study NCT04823052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gaboxadol (HLX-0206)
Description: Gaboxadol (HLX-0206) Capsule
Study NCT04883450 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging (MRI)
Description: All enrolled participants will undergo magnetic resonance imaging (MRI) at their Baseline and 18-Month follow-up visit
Study NCT05363241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency in classical targets (CRF-CT)
Description: Participant will take Midazolam 2 mg as a sedative, and will be positioned on a fluoroscopy table in a supine posture, with a pillow under the knee allowing the knee in a slightly flexed position. The skin and subcutaneous tissues will be anesthetized with 2 mL of 1% lidocaine under sterile circumstances. Patients will undergo motor block tests, using 45 volts and 2 hertz, prior to the CRF itself, to ensure that no motor structures will be affected. If the motor test is negative, the CRF procedure will follow, using COOLIEF needles guided by fluoroscopy. A cooled technical chamber will be used, at a temperature of 60° and application for 150 seconds. The targets will be the genicular nerves superior medial, superior lateral, and inferior medial. The participant will not be able to follow the procedure.
Study NCT05363241 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency in revised targets (CRF-RT)
Description: Participant will take Midazolam 2 mg as a sedative, and will be positioned on a fluoroscopy table in a supine posture, with a pillow under the knee allowing the knee in a slightly flexed position. The skin and subcutaneous tissues will be anesthetized with 2 mL of 1% lidocaine under sterile circumstances. Patients will undergo motor block tests, using 45 volts and 2 hertz, prior to the CRF itself, to ensure that no motor structures will be affected. If the motor test is negative, the CRF procedure will follow, using COOLIEF needles guided by fluoroscopy. A cooled technical chamber will be used, at a temperature of 60° and application for 150 seconds. The targets will be the genicular nerves superior medial, superior lateral, and inferior medial and recurrent fibular nerves and the infra-patellar branch of the saphenous nerve. The participant will not be able to follow the procedure.
Study NCT06571578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold Inspiratory muscle trainer
Description: threshold inspiratory muscle trainer device Each subject will breathe through a separate mouthpiece through attach the mouthpiece firmly While putting a nose clip and inhale deeply through the mouthpiece to generate an inspiratory pressure greater than the indicated presetting threshold pressure to compress the spring and open the valve. Using High - intensity interval training technique
Study NCT03289260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Description: Patients receive topical Imiquimod therapy for 12 weeks.
Study NCT03289260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Patients receive topical Doritin therapy for 12 weeks
Study NCT03289260 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fulguration
Description: Surgical Excision and Fulguration of condyloma
Study NCT03289260 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fulguration
Description: Surgical Excision and Fulguration of condyloma
Study NCT05044962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir/ Rilpivirine
Description: For initial injection participants will be given CABENUVA 600-mg/900-mg Kit: (single-dose vial of 600 mg/3 mL (200 mg/mL) cabotegravir , single-dose vial of 900 mg/3 mL (300 mg/mL) rilpivirin).~For subsequent injections participants will be given CABENUVA 400-mg/600-mg Kit: (single-dose vial of 400 mg/2 mL (200 mg/mL) cabotegravir, single-dose vial of 600 mg/2 mL (300 mg/mL) rilpivirine)~CABENUVA® is owned by or licensed to the ViiV Healthcare group of companies, GlaxoSmithKline Research Triangle Park, NC 27709
Study NCT05044962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabotegravir/ Rilpivirine
Description: For initial injection participants will be given CABENUVA 600-mg/900-mg Kit: (single-dose vial of 600 mg/3 mL (200 mg/mL) cabotegravir , single-dose vial of 900 mg/3 mL (300 mg/mL) rilpivirin).~For subsequent injections participants will be given CABENUVA 400-mg/600-mg Kit: (single-dose vial of 400 mg/2 mL (200 mg/mL) cabotegravir, single-dose vial of 600 mg/2 mL (300 mg/mL) rilpivirine)~CABENUVA® is owned by or licensed to the ViiV Healthcare group of companies, GlaxoSmithKline Research Triangle Park, NC 27709
Study NCT05044962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel (ETG) implant
Description: Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm
Study NCT05044962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular depo-medroxyprogesterone acetate (IM DMPA)
Description: DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide
Study NCT05044962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular depo-medroxyprogesterone acetate (IM DMPA)
Description: DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide
Study NCT05044962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Description: Contraceptive estrogen implants are thin rods inserted under the skin of a woman's arm
Study NCT05044962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NNRTI, PI, or INSTI-containing 1st or 2nd line ART regimens
Description: ART that concurrently contains combinations of non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz, and protease-inhibitors (PIs), such as atazanavir/ritonavir or lopinavir/ritonavir, or integrase inhibitors (INSTIs), such as raltegravir or dolutegravir
Study NCT06571578 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: posture correction exercises
Description: conventional exercise consists of~* Cervical isometric exercises will be performed in the sitting position by resisting at the forehead (cervical ﬂexion, extension, rotation and side bending) for 10 seconds with 15 seconds breaks between holds with 10-15 repetitions in a progressive manner 3time/week for 12 weeks.~* Postural correction exercise consists of gently rolling of pelvis forward to an upright neutral sitting position, followed by scapular correction and occipital lift. Also, for the sub-occipital muscles stretching~* stretching exercises for scalene and levator muscles
Study NCT06571578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: posture correction exercises
Description: conventional exercise consists of~* Cervical isometric exercises will be performed in the sitting position by resisting at the forehead (cervical ﬂexion, extension, rotation and side bending) for 10 seconds with 15 seconds breaks between holds with 10-15 repetitions in a progressive manner 3time/week for 12 weeks.~* Postural correction exercise consists of gently rolling of pelvis forward to an upright neutral sitting position, followed by scapular correction and occipital lift. Also, for the sub-occipital muscles stretching~* stretching exercises for scalene and levator muscles
Study NCT06571071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: De-Stress and Chill Gummies-U001
Description: Two gummies in sequence daily after meal for 60 days
Study NCT06571071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: De-Stress and Chill Gummies-I001
Description: Two gummies in sequence daily after meal for 60 days
Study NCT06571071 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gummies-001
Description: Two gummies in sequence daily after meal for 60 days
Study NCT05295953 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TBS
Description: Four sessions of TBS at 120 % resting motor threshold, delivered using MagVenture B65 A/P coil, each lasting 10 minutes and separated by 50 minutes intervals. Targeting will be done using neuronavigation and processed resting state brain scan.
Study NCT05295953 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham TMS
Description: Four sessions of sham TMS delivered using MagVenture B65 A/P coil.
Study NCT04830644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Iguratimod orally twice a day
Study NCT04830644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally twice a day
Study NCT03950037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Albendazole; 15 mg/k/d divided in two doses (morning and evening), for 30 days, with a ceiling in 1200 mg/d.
Study NCT06239116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)
Description: Single ascending dose of RM-718 or placebo (matched to specific RM-718 Part A dose cohort)
Study NCT06202937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother Baby Yoga
Description: Fragile Baby Perception Syndrome, Maternal Attachment, Depression-Anxiety-Stress Level
Study NCT06202937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention:control
Description: the control group received the usual care
Study NCT05168644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide Inhalation Powder
Description: Investigational drug will be supplied as capsules, each capsule contains 0.25 mg or 1 mg of Niclosamide Inhalation Powder. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
Study NCT05168644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as capsules, each capsule will contain no active ingredient. The capsules will be administered with the provided breath actuated Plastiape RS00 Model 8 Dry Powder Inhaler device.
Study NCT06340789 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Benzoate 2gram/day
Description: the add-on sodium benzoate with conventional pharmacological treatment
Study NCT06340789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the add-on placebo with conventional pharmacological treatment
Study NCT06239116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: RM-718 or placebo (matched to specific RM-718 dose cohort)
Description: Multiple ascending doses of RM-718 or placebo (matched to specific RM-718 Part B dose cohorts)
Study NCT06239116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part C: RM-718
Description: Multiple ascending doses of RM-718 (specific to Part C dose cohorts)
Study NCT05720611 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Digitally delivered gardening and healthy eating course
Description: The intervention group will consist of a digitally delivered course designed to teach gardening, cooking and nutrition education to adults with risk factors for CVD. Participants will be invited to participate in 10 Zoom-based gardening and cooking education sessions. Zoom meetings will be facilitated by members of the study team, will present information to participants and will allow participants to ask questions and share their experiences with others. The materials will walk the participant through various aspects of starting and tending a garden.
Study NCT05720611 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digitally delivered gardening and healthy eating course
Description: The intervention group will consist of a digitally delivered course designed to teach gardening, cooking and nutrition education to adults with risk factors for CVD. Participants will be invited to participate in 10 Zoom-based gardening and cooking education sessions. Zoom meetings will be facilitated by members of the study team, will present information to participants and will allow participants to ask questions and share their experiences with others. The materials will walk the participant through various aspects of starting and tending a garden.
Study NCT05079464 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS
Description: All participants randomized to tDCS will receive active tDCS